title: Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy.
abstract: We investigated the baseline levels of urine nuclear matrix protein 22 (U-NMP22) and survivin in urine after radical cystectomy for primary invasive bladder cancer. We measured U-NMP22 and survivin values in 72 patients with four types of urinary diversion (Indiana bladder, Bricker bladder, Mainz bladder and orthotopic bladder) after radical cystectomy and 25 healthy volunteers. We also analyzed the relation between the U-NMP22 and survivin level and other variables among patients with continent urinary diversion and incontinent urinary diversion as well as healthy controls, and found that the U-NMP22 and survivin values were not associated with postoperative interval or gender. The U-NMP22 values (mean ± standard error) for continent urinary diversion, incontinent urinary diversion and healthy controls were 12.08 ± 0.10, 16.62 ± 0.15 and 0.01 ± 0.00 U/ml, respectively. The survivin values (mean ± standard error) for continent urinary diversion, incontinent urinary diversion and healthy controls were 0.47 ± 0.06, 0.69 ± 0.16 and 0.02 ± 0.03 U/ml, respectively. The U-NMP22 and survivin values in the Bricker bladder group were significantly higher than the values in the other three groups. We noted that increased levels of U-NMP22 and survivin after radical cystectomy varied according to different predictors, which may be useful for designing strategies to follow these cases.
authors: Second Hospital of Lanzhou University, Lanzhou, China.
authors: Zhi-Long
authors: ZL
authors: Dong
authors: Ze-Ping
authors: ZP
authors: Lu
authors: Han-Zhang
authors: HZ
authors: Wang
authors: Li-Yuan
authors: LY
authors: Zhang
authors: Zhi-Ping
authors: ZP
authors: Wang
authors: Yu-Fang
authors: YF
authors: Zhang
authors: Bao-Liang
authors: BL
authors: Ma
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000652:urine*; D016022:Case-Control Studies; D002681:China; D015653:Cystectomy / Q000009:adverse effects; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000652:urine*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000652:urine*; D009687:Nuclear Proteins / Q000652:urine*; D018570:Risk Assessment; D012307:Risk Factors; D000077022:Survivin; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery* / Q000652:urine*; D014547:Urinary Diversion / Q000009:adverse effects; D014549:Urinary Incontinence / Q000209:etiology / Q000652:urine
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D009687:Nuclear Proteins; D000077022:Survivin; C100379:nuclear matrix protein 22